Daiwa downgraded Eli Lilly to Outperform from Buy with a price target of $610, down from $660.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Amgen upgraded to Outperform from Market Perform at BMO Capital
- Organon, Eli Lilly enter migraine medicine commercialization agreement in Europe
- Eli Lilly extends expiration of tender offer to acquire Point Biopharma
- Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
- Billionaire Ken Griffin Bets Big on 2 ‘Strong Buy’ Stocks — Eli Lilly and Microsoft
